Author:
Mann Jacqueline E.,Smith Joshua D.,Kulkarni Aditi,Foltin Susan K.,Scheftz Erin B.,Murray Isabel R.,Gensterblum-Miller Elizabeth,Brummel Collin V.,Bhangale Apurva,Hoesli Rebecca C.,Brenner J. Chad
Subject
Cancer Research,Oncology,Oral Surgery
Reference56 articles.
1. Changes in survival in head and neck cancers in the late 20th and early 21st century: a period analysis;Pulte;Oncotarget,2010
2. Head and neck squamous cell carcinoma;Johnson;Nat Rev Dis Primers,2023
3. Prognostic factors and long-term survivorship in patients with recurrent or metastatic carcinoma of the head and neck;Argiris;Cancer,2004
4. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study;Burtness;Lancet,2019
5. Sacco AG, Chen R, Worden FP, Wong DJL, Adkins D, Swiecicki, et al. Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial. Lancet Oncol 2021;22(6):883-92.
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献